Can a counseling program restore intimacy after rectal cancer?
NCT ID NCT00712751
First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time
Summary
This study tests whether a specialized sexual health education program can help people who have been treated for rectal, colorectal, or anal cancer improve their sexual function and emotional well-being. Participants are randomly assigned to either the new counseling program or standard care, and their sexual function and distress are measured over time. The goal is to see if this type of support can ease the sexual challenges that often follow cancer treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- A structured sexual health educational counseling program
- What this could lead to
- If effective, this program could become a standard support tool to help rectal cancer survivors regain sexual confidence and emotional well-being.
- What could go wrong
- This is a small pilot study, so results may not apply broadly. The program's benefit over usual care is unproven, and individual outcomes may vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
149 people
The number who actually took part.
- Started
-
Jun 2008
- Finished
-
Nov 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Colorectal patients
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * At least six months post radiation and/or surgery for stage I-III rectal adenocarcinoma or rectosigmoid for cancer with an anastomosis at 15 cm or below and completed treatment * At least six months post radiation and/or chemotherapy for anal cancer. * Have no evidence of disease or recurrence * For women indicate Indicate moderate satisfaction or below on their overall sexual life (a score of "4" or lower on the question "Over the past 4 weeks, how satisfied have you been with your overall sexual life?" * For men indicate, and a score of "3" or lower on the question "How would you rate your confidence that you could get and keep an erection" for men) and a score of "2" or higher on the question "How much does this problem bother you? * In the judgment of the consenting professional interventionists, able to communicate in English well enough to work with English speaking and complete the study assessments. * Age 21 years or older. Exclusion Criteria: * Significant cognitive or psychiatric disturbance sufficient, in the investigator's judgment, to preclude participation in a psychotherapeutic intervention. * Are actively participating in protocol 06-151 * Participated in focus group or qualitative interview.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anal cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A phase II study of total neoadjuvant mFOLFOX6 plus suvemcitug and enlonstobart with selective omission of pelvic radiotherapy for High-Risk Mid-Rectal locally advanced rectal cancer with MSS status
- Leveraging digital health solutions to collect Patient-Reported outcomes in rectal cancer
- Can a targeted drug conjugate outsmart advanced colorectal cancer?
- Can Pre-Surgery radiation stop rectal cancer from returning?
- Can a platform trial match the right drug combo to each tumor?
- Laser light may help surgeons spot risky bowel connections